As per Data Bridge Market Research analysis, the daratumumab market was valued at USD 12.86 billion in 2025 and is projected to reach USD 19.29 billion by 2033, growing at a CAGR of 5.20% from 2026 to 2033. Growth is being driven by the rising global incidence of multiple myeloma, continued label expansion of daratumumab-based regimens into earlier and higher-risk disease settings, and sustained conversion from intravenous to subcutaneous administration.
2 vistas